Sparsentan, an endothelin type A (ETA) and AT1R antagonist, was shown to prevent disruption of actin cytoskeleton in experimental FSGS (207), and its protective effects were also evident in a phase 2 study involving patients with FSGS (208–210). The gene discussed is AGTR1; the disease is focal segmental glomerulosclerosis.